ASX:IXC

Invex Therapeutics Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive IXC News and Ratings via Email

Sign-up to receive the latest news and ratings for Invex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Invex Therapeutics

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Subiaco, Australia.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Invex Therapeutics (ASX:IXC) Frequently Asked Questions

What stocks does MarketBeat like better than Invex Therapeutics?

Wall Street analysts have given Invex Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Invex Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Invex Therapeutics' key executives?

Invex Therapeutics' management team includes the following people:
  • Ms. Narelle Warren B.Com., L.L.B., B.Com, LLB, CFO & Company Sec.
  • Prof. Alexandra Jean Sinclair, Exec. Director & Chief Scientific Officer

Who are some of Invex Therapeutics' key competitors?

What is Invex Therapeutics' stock symbol?

Invex Therapeutics trades on the ASX under the ticker symbol "IXC."

How much money does Invex Therapeutics make?

Invex Therapeutics has a market capitalization of $0.00.

What is Invex Therapeutics' official website?

The official website for Invex Therapeutics is www.invextherapeutics.com.

How can I contact Invex Therapeutics?

The company can be reached via phone at 61 8 6382 0137.


This page was last updated on 8/3/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.